ArticleFrontiers in cell and developmental biology2026
Leveraging PANoptosis-associated genes for unraveling implication of decidualization deficiency in pre-eclampsia via transcriptome data and experiment validation.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Decidualization deficiency is a key pathological feature of pre-eclampsia (PE) and is closely associated with aberrant regulation of cell fate. PANoptosis is a recently characterized form of inflammatory programmed cell death that has been implicated in several pregnancy-related disorders. However, its potential involvement in decidualization deficiency in PE remains poorly understood. This study aimed to explore the association between PANoptosis-related genes and decidualization deficiency in PE, and to identify candidate biomarkers and potential therapeutic targets related to PANoptosis. Methods: Datasets containing decidual tissue samples derived from women with PE and normal controls were acquired in the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified and subjected to enrichment analysis. After that, PANoptosis-related genes were intersected with DEGs derived from the decidual tissue of PE, followed by protein-protein interaction (PPI) network construction and correlation analysis. Next, the immune infiltration landscape and its association with PANoptosis-related DEGs were assessed. Furthermore, three machine learning algorithms, including support vector machine-recursive feature elimination (SVM-RFE), the least absolute shrinkage and selection operator (LASSO), and the random forest (RF) algorithms, were adopted to identify potential diagnostic biomarkers for PE. Artificial neural network (ANN) and nomogram models were then constructed and evaluated in testing datasets, which included decidual stromal cell samples derived from women with PE and normal controls. Additionally, the expression of PANoptosis-related signature genes and decidualization-related markers was experimentally validated in primary human decidual stromal cells (HDSCs) derived from PE patients and healthy controls. In addition, consensus clustering analysis was conducted on the basis of signature genes, and immune infiltration landscape analysis of different subtypes of PE was performed. Ultimately, the candidate compounds targeting the signature genes were screened and then further verified Results: 430 DEGs were determined, and enrichment analysis indicated that these DEGs were mainly involved in inflammation, apoptosis, and dysfunction of decidual tissue in PE. Then, 10 PANoptosis-related DEGs in PE were further screened. Following that, immune landscape analysis revealed an aberrant abundance of various immunocytes and the levels of immune checkpoints in the decidual tissue of PE, which were closely associated with the PANoptosis-related DEGs. Next, through machine learning, nine PANoptosis-related signature genes ( Conclusion: This study suggests a potential association between PANoptosis-related molecular dysregulation and decidualization deficiency in PE. The identified PANoptosis-related signature genes may serve as candidate biomarkers with predictive relevance, and melatonin may represent a potential therapeutic candidate targeting PANoptosis-related pathways. These findings provide a foundation for future mechanistic and translational studies on PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.